COVID-19 Vaccination Information
The Louisiana Department of Health is coordinating the COVID-19 vaccine distribution effort in Louisiana. As more vaccines become available from the CDC, more individuals and groups will be offered a vaccination.
Limited amounts of COVID vaccines are available at select locations only for:
- Persons 65 and older
- Dialysis providers and patients
- Ambulatory and outpatient providers and staff
- Behavioral health providers and staff
- Urgent care clinic providers and staff
- Community care providers and staff
- Dental providers and staff
- Non-emergency Medical Transportation (NEMT) providers and staff
- Professional home care providers (including hospice workers) and home care recipients (including older and younger people with disabilities over the age of 16 who receive community or home-based care, as well as clients of home health agencies)
- American Sign Language (ASL) and foreign language interpreters and Support Service Providers (SSPs) working in community and clinic-based settings, and clients who are both deaf and blind
- Health-related support personnel (lab staff, mortuary staff who have contact with corpses, pharmacy staff)
- Schools of allied health students, residents and staff
- Law enforcement and other first responders
- Louisiana Unified Command Group
- State and local essential COVID emergency response personnel
- Some elections staff ahead of March and April elections
- Teachers and any other support staff working on site in K-12 or daycare
- All pregnant persons
- Individuals ages 55-64 with at least one of the conditions listed by the CDC as placing them at an “increased risk of severe illness from the virus that causes COVID-19." Persons with the following qualifying underlying medical conditions are advised to complete the Louisiana COVID-19 Vaccine Attestation Form, before their appointment, to receive the vaccine:
- Chronic kidney disease
- COPD (chronic obstructive pulmonary disease)
- Down syndrome
- Heart conditions including but not limited to heart failure, coronary artery disease or cardiomyopathies
- Immunocompromised state (weakened immune system) from solid organ transplant
- Obesity (body mass index [BMI] of 30kg/m2 or higher but less than 40kg/m2)
- Severe obesity (BMI greater than 40kg/m2)
- Sickle cell disease
- Type 2 diabetes mellitus
Patients must contact a participating location and make an appointment at the location. Do not arrive at a location without an appointment. LDH cannot make appointments for residents; only participating locations can. Appointments do not have to be made to receive the second dose of the vaccine. Second doses are given at the same location a person receives their first dose and the appointment for the second dose will be made during the appointment for the first dose.
Vaccine Communication Materials
- So You Have Covid-19: Have You Considered Monoclonal Antibody Treatment?: English | Spanish | Vietnamese
- Help Others Who Qualify for a Vaccine:
- How Much Does It Cost?:
- Scheduling a COVID Vaccine:
- COVID-19 Vaccine FAQs
- FAQ Graphics: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
- FAQs about Long-Term Care Pharmacy Partnerships
- Clinical Trials and Safety: English | Spanish | Vietnamese
- Who Gets It Now:
- Who Gets It Next:
- Vaccine Fact Sheet (What You Need to Know): English | Spanish | Vietnamese
- Vaccine Recipient Q & A: English | Spanish | Vietnamese
- Safe and Effective:
- How it Works:
- Light at the End of the Tunnel:
Reporting Adverse Reactions
After a vaccine is authorized or approved for use, many vaccine safety monitoring systems watch for adverse events (possible side effects). This continued monitoring can pick up on adverse events that may not have been seen in clinical trials. If an unexpected adverse event is seen, experts quickly study it further to assess whether it is a true safety concern. Experts then decide whether changes are needed in U.S. vaccine recommendations. This monitoring is critical to help ensure that the benefits continue to outweigh the risks for people who receive vaccines.
Immediately (24/7) report severe COVID-19 vaccine reactions requiring hospitalization to the Office of Public Health (OPH) at 1-800-256-2748. For more information, view the Health Alert Networks Message 20-52: COVID-19 Vaccination Severe/Allergic Reaction Reporting.
v-safe is a smartphone-based tool that uses text messaging and web surveys to provide personalized health check-ins after you receive a COVID-19 vaccination. Through v-safe, you can quickly tell CDC if you have any side effects after getting the COVID-19 vaccine. Depending on your answers, someone from CDC may call to check on you and get more information. V-safe will also remind you to get your second COVID-19 vaccine dose if needed. For more information, click here.
Vaccine Adverse Emergency Reporting System (VAERS)
VAERS is a national early warning system to detect possible safety problems in U.S.-licensed vaccines. VAERS is co-managed by the Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA). VAERS accepts and analyzes reports of adverse events (possible side effects) after a person has received a vaccination. Anyone can report an adverse event to VAERS. Healthcare professionals are required to report certain adverse events and vaccine manufacturers are required to report all adverse events that come to their attention.
Achieving Herd Immunity Through Vaccinations
To access more information on COVID-19 vaccines and Herd Immunity, click here.
Federal Pharmacy Partnership for LTC Program in Louisiana
All licensed LTCs in Louisiana are set to receive on-site COVID-19 vaccinations through either Walgreens or CVS. Click here for more information.
To view a U.S. Health and Human Services video called "Tell Me More About Vaccines" click here.
- 8 things to know
- How the CDC is making vaccine recommendations?
- Ensuring the safety of vaccines
- Frequently Asked Questions
Below are other key updates on the COVID-19 vaccine:
- The Louisiana Department of Health’s (LDH) Office of Public Health will follow the CDC's Advisory Committee for Immunization Practices (ACIP) to guide recommendations on which populations should be vaccinated with any of the COVID-19 vaccines that come on to the market after FDA approval.
- A multi-platform communications and marketing plan is being developed that includes steps for conducting outreach to groups most affected by COVID-19 and continues efforts to ensure reaching the most vulnerable groups and underserved areas.
- Public health officials will be reaching out proactively to vaccination sites to ensure that the infrastructure and systems are in place for populations to receive vaccinations as soon as they become available in Louisiana.